Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
Author:
Funder
Wellcome Trust
Cancer Research UK
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/29/2/490/23980175/mdx717.pdf
Reference11 articles.
1. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy;Eggermont;N Engl J Med,2016
2. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials;Santiago-Walker;Clin Cancer Res,2015
3. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma;Gray;Oncotarget,2015
4. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study;Corrie;Lancet Oncol,2014
5. Final version of 2009 AJCC melanoma staging and classification;Balch;J Clin Oncol,2009
Cited by 118 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Promising and Minimally Invasive Biomarkers: Targeting Melanoma;Cells;2023-12-20
2. Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients;Frontiers in Oncology;2023-12-19
3. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer;BMC Medicine;2023-12-12
4. Liquid biopsy for assessment of RFS (recurrence-free survival) in NSCLC (non-small cell lung cancer) patients post-treatment through circulating tumour DNA detection: A meta-analysis;The Journal of Liquid Biopsy;2023-12
5. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0;Journal for ImmunoTherapy of Cancer;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3